Loading
PAPMET was the first randomised trial dedicated to papillary kidney cancer; cabozantinib held the disease back for longer than sunitinib, the previous default, while two more selective MET inhibitors did not.
Papillary renal cell carcinoma had been treated with drugs developed for clear cell disease. PAPMET, a SWOG-led randomised phase 2 trial, assigned 152 patients with metastatic papillary renal cell carcinoma, untreated or after one prior therapy, to sunitinib or to one of three MET-directed inhibitors: cabozantinib, crizotinib or savolitinib. The primary endpoint was progression-free survival against sunitinib.
The crizotinib and savolitinib arms were closed early for futility. Cabozantinib lengthened progression-free survival and produced more responses than sunitinib, and became the preferred single agent for papillary disease in guidelines, later joined by immunotherapy combinations tested in single-arm studies.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
152 enrolled.
Shares Sunitinib, Anti-angiogenic therapy, Renal cell carcinoma, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Exelixis, Cabozantinib, Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Anti-angiogenic therapy, Small-molecule kinase inhibitors and the tag subtype-trials.
Shares Renal cell carcinoma and the tag subtype-trials.
Shares Anti-angiogenic therapy and the tag subtype-trials.
Shares Anti-angiogenic therapy and the tag subtype-trials.